Pages that link to "Q40025669"
Jump to navigation
Jump to search
The following pages link to Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. (Q40025669):
Displaying 12 items.
- Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study (Q29030107) (← links)
- The development of nomograms for stratification of men at risk of prostate cancer prior to prostate biopsy. (Q38165242) (← links)
- Evolution and immediate future of US screening guidelines (Q38203982) (← links)
- International perspectives on screening. (Q38203983) (← links)
- Prostate-specific antigen-based prostate cancer screening: Past and future (Q38408501) (← links)
- Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (Q38789338) (← links)
- Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator? (Q40152616) (← links)
- Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population. (Q41114614) (← links)
- Urological oncology in the BJUI. (Q45180361) (← links)
- Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic. (Q55139905) (← links)
- Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population (Q88870987) (← links)
- Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore (Q90353952) (← links)